Krystal Biotech Inc - Asset Resilience Ratio
Krystal Biotech Inc (KRYS) has an Asset Resilience Ratio of 27.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read KRYS total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Krystal Biotech Inc's Asset Resilience Ratio has changed over time. See Krystal Biotech Inc (KRYS) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Krystal Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Krystal Biotech Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $338.46 Million | 27.29% |
| Total Liquid Assets | $338.46 Million | 27.29% |
Asset Resilience Insights
- Very High Liquidity: Krystal Biotech Inc maintains exceptional liquid asset reserves at 27.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Krystal Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Krystal Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Krystal Biotech Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Krystal Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.93% | $252.65 Million | $1.06 Billion | +2.69pp |
| 2023-12-31 | 21.24% | $173.85 Million | $818.36 Million | -17.66pp |
| 2022-12-31 | 38.91% | $217.27 Million | $558.45 Million | +23.44pp |
| 2021-12-31 | 15.46% | $96.85 Million | $626.29 Million | +14.50pp |
| 2020-12-31 | 0.96% | $2.99 Million | $310.84 Million | -1.99pp |
| 2019-12-31 | 2.95% | $6.17 Million | $209.02 Million | -4.02pp |
| 2018-12-31 | 6.97% | $8.09 Million | $116.12 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $50.11 Million | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical tr… Read more